Usage Examples
- The FIH protocol goes into the original IND, so the 30-day clock covers it.
- We are dosing two sentinel subjects 24 hours ahead of the rest of cohort 1.
- Cohort 3 hit a dose-limiting toxicity, so the safety review committee has to clear escalation before cohort 4 opens.
What is First-in-Human Study (FIH)?
A first-in-human study is the first administration of an investigational drug or biologic to human subjects, run under an IND in effect, to establish tolerability, pharmacokinetics, and a safe dose range before efficacy is tested.
A first-in-human study exists because animal data eventually stops answering the question. No species predicts human tolerability well enough to justify skipping the step, so the first human exposure is deliberately small, staged, and instrumented. FIH studies convert a nonclinical safety argument into observed human tolerability, pharmacokinetics, and a dose range that every later trial depends on.
A first-in-human study covers the initial introduction of an investigational drug into humans, sitting inside Phase 1, a stage that generally runs 20 to 80 subjects. FIH measures metabolism, pharmacologic action, and side effects at increasing doses. It stops short of efficacy: the study is not powered for a clinical endpoint, and any early signal is hypothesis-generating, not evidence of effectiveness.
A first-in-human study is applied through the IND. The FIH protocol goes into the original submission alongside the pharmacology and toxicology package supporting the sponsor's conclusion that dosing humans is reasonably safe, and dosing waits until the IND is in effect thirty days after FDA receives it. FIH conduct then runs on staggered cohorts, sentinel dosing, and a safety review committee that clears each escalation.
Not to be confused with
- Phase 1 study
- every FIH study is a Phase 1 study, but Phase 1 also holds drug-interaction, food-effect, and special-population studies run long after the first exposure. FIH is one event; Phase 1 is the whole stage.
- IND-enabling studies
- the nonclinical toxicology and safety pharmacology work that has to exist before humans can be dosed. IND-enabling studies end exactly where FIH begins; they are the evidence, not the trial.
- Exploratory IND study
- a separate FDA pathway for very limited early human exposure under a reduced nonclinical package. It can precede a conventional FIH study but does not replace it, because it is not designed to establish a tolerated dose range.
- First-in-patient study
- the first dosing in the target disease population. When FIH runs in healthy volunteers, first-in-patient is a separate later study; in oncology the two are usually the same study.
The obligations below come from the IND regulations that govern the first dose in humans.
What you must do
- 1Submit pharmacology and toxicology information adequate to support the sponsor's conclusion that it is reasonably safe to conduct the proposed investigation, and name the individuals who evaluated the data and reached that conclusion21 CFR 312.23(a)(8)
- 2Include the FIH protocol itself in the IND, and route any protocol not submitted initially through the amendment procedure rather than opening it quietly21 CFR 312.23(a)(6)
- 3Hold all dosing until the IND is in effect, which is 30 days after FDA receives it unless FDA imposes a clinical hold21 CFR 312.40(b)(1)
- 4Design the study against Phase 1 objectives — metabolism, pharmacologic action, and side effects at increasing doses — rather than against an efficacy endpoint21 CFR 312.21(a)(1)
Common mistakes
Counting the 30 days from the date you hit send
the clock runs from FDA receipt, not from courier pickup or gateway submission, and a clinical hold stops it entirely. Sites book screening visits off the wrong date and end up with a first dose administered before the IND was in effect, which is an unapproved-drug violation, not a scheduling slip.
Loading efficacy endpoints into the FIH protocol
a study sized for 20 to 80 subjects across ascending cohorts cannot support an effectiveness claim, and exploratory endpoints invite escalation decisions made on noise. The cost is a dose range defended with weak data in the Phase 2 protocol and at the end-of-Phase-2 meeting.
Treating the pharm/tox section as a filing formality
that section is the entire basis on which FDA permits human dosing, and it must carry the named evaluators and their reasonably-safe conclusion. A package that cannot support that conclusion on its own terms is what turns a 30-day review into a clinical hold.
When This Matters
- The FIH protocol goes into the original IND, so the 30-day clock covers it.
- We are dosing two sentinel subjects 24 hours ahead of the rest of cohort 1.
- Cohort 3 hit a dose-limiting toxicity, so the safety review committee has to clear escalation before cohort 4 opens.
Frequently Asked Questions
Thirty days after FDA receives the IND, unless FDA notifies the sponsor that the investigation is subject to a clinical hold. There is no approval letter to wait for. The IND takes effect on its own at day 30, and dosing the first subject before that date is a violation.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Clinical Workflows
Track clinical trial regulations across global markets
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
Related Regulatory Intelligence
Related Actions
Sources & References
- 21 CFR 312.21 - Phases of an investigation
- 21 CFR 312.23 - IND content and format
- 21 CFR 312.40 - General requirements for use of an investigational new drug in a clinical investigation
- ICH M3(R2) - Nonclinical Safety Studies for the Conduct of Human Clinical Trials
- FDA Guidance for Industry, Investigators, and Reviewers - Exploratory IND Studies
